drugset / Trial / NCT04589663

Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma

NCT04589663

Phase 2 Completed 24 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This clinical study was designed to assess the pharmacokinetics, safety and tolerability of single inhaled doses of mometasone furoate (MF) when administered alone via MF Twisthaler® (TH) or as an indacaterol acetate/MF fixed dose combination (QMF149) via the Concept 1 (C1) device in pediatric asthma patients.

Timeline

Start
2021-06-07
Primary completion
2022-04-11
Completion
2022-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 75 ug Inhaled
Subject Mometasone furoate Other / unclassified 40 ug Inhaled
Subject Mometasone furoate Other / unclassified 100 ug Inhaled
Background Budesonide Small molecule
Background Salbutamol Unknown

Indications